Massive 5,000-Person study launches to map the journey of rare blood cancers

NCT ID NCT07362225

Summary

This is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from their medical records and their own reports on symptoms and quality of life. The goal is to identify patterns in how the disease progresses and responds to treatments to guide future research and improve patient care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MPN Research Foundation

    RECRUITING

    Chicago, Illinois, 60654, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACCELERATED PHASE MPN ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASM AGNOGENIC MYELOID METAPLASIA BLAST PHASE MPN BLAST PHASE MYELOPROLIFERATIVE NEOPLASM CHRONIC IDIOPATHIC MYELOFIBROSIS ESSENTIAL THROMBOCYTHEMIA, ET ET (ESSENTIAL THROMBOCYTHEMIA) IDIOPATHIC MYELOFIBROSIS MDS/MPN CROSSOVER SYNDROMES MF MPN MPN (MYELOPROLIFERATIVE NEOPLASMS) MPN-ASSOCIATED MYELOFIBROSIS MYELOFIBROSIS MYELOFIBROSIS (MF) MYELOFIBROSIS (PMF) MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH HIGH MOLECULAR RISK MUTATIONS MYELOFIBROSIS, POST ET MYELOFIBROSIS, POST PV MYELOFIBROSIS, PRIMARY MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS MYELOPROLIFERATIVE DISORDER MYELOPROLIFERATIVE DISORDERS MYELOPROLIFERATIVE DISORDERS (MPD) MYELOPROLIFERATIVE NEOPLASM WITH 10% BLASTS OR HIGHER MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS (MPNS) POLYCYTHEMIA VERA POLYCYTHEMIA VERA (PV) POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) POST-ET MF POST-POLYCYTHEMIA VERA MYELOFIBROSIS POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) POST-PV MF PRE-FIBROTIC MYELOFIBROSIS PRIMARY MYELOFIBROSIS (MF) PRIMARY MYELOFIBROSIS (PMF) SECONDARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS (POST-POLYCYTHEMIA VERA MYELOFIBROSIS, POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS) SECONDARY MYELOFIBROSIS IN MYELOPROLIFERATIVE DISEASE THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) THROMBOCYTHEMIA, ESSENTIAL THROMBOCYTHEMIA, HEMORRHAGIC